• Uncategorized

Early Time-of-Day Immunotherapy Shows Survival Benefit in Lung Cancer Trial

In a Chinese phase 3 trial (LungTIME-C01) involving 210 patients with advanced non-small cell lung cancer, administering anti-PD-1 immunotherapy before…